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Background: Anthocyanins may protect against cardiovascular related cognitive
decline and dementia.
Objective: Open-label study to measure changes in serum lipids, glucose, glycosylated
hemoglobin (HbA1c), and markers of inflammation after anthocyanin supplementation
in people with increased risk of dementia. As a secondary endpoint we examined
potential changes in a battery of cognitive test in the anthocyanin group (AG). A total
of 27 individuals with mild cognitive impairment (MCI) (n = 8) or stable non-obstructive
coronary artery disease (CAD) (n = 19) consumed two Medox R© capsules, each
containing 80 mg of natural purified anthocyanins, twice daily for 16 weeks. They
provided blood samples and performed a short battery of cognitive tests. Twenty
healthy normal controls (NC) (n = 20) provided blood samples, but did not receive any
intervention and did not perform cognitive tests.
Results: There was a significant difference between groups for CCL-5/RANTES
[regulated on activation, normal T-cell expressed and secreted (RANTES)]. In addition,
total cholesterol and triglycerides were significantly increased in the AG. Improvements
in memory and executive test scores were observed. No adverse effects were reported.
Conclusion: The results of this pilot study were largely inconclusive with regard
to the potential protective effects of anthocyanin supplementation. However,
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anthocyanins were well tolerated, and compliance was high. Larger, placebo-
controlled studies to explore the potential effects of anthocyanins on dementia risk
are encouraged.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02409446.
Keywords: mild cognitive impairment, MCI, anthocyanins, lipids, inflammation markers
INTRODUCTION
Anthocyanins, a subclass of the flavonoids, are found in foods
such as berries and fruits and information regarding their content
in food can be found in an online phenol-explorer (Neveu et al.,
2010). Anthocyanins have been shown in previous studies to
have a number of positive health effects, such as improving the
blood lipid profile (Qin et al., 2009; Li et al., 2015), and also
fasting serum glucose and glycosylated hemoglobin (HbA1c) in
diabetic patients (Li et al., 2015; Yang et al., 2017), and have
anti-inflammatory effects (Xia et al., 2007; Spencer et al., 2012;
Spagnuolo et al., 2017). Anthocyanins can improve endothelial
and vascular function (Rodriguez-Mateos et al., 2013, 2016,
2019), and can cross the blood–brain barrier (Faria et al., 2014)
and thus may reduce neurodegenerative and cerebrovascular
changes and possibly protect against cognitive decline and
dementia. Interestingly, some studies have found that food-
based anthocyanins can improve memory functioning in older
adults with mild cognitive impairment (MCI; Krikorian et al.,
2010a,b; Hein et al., 2019). However, these studies were based on
relatively small samples, and had a short duration. In addition,
food-based anthocyanin supplementation leads to heterogeneity,
i.e., variations in types of food sources, concentration, and dose
of anthocyanins.
In this exploratory open-label pilot study, we aimed
as a primary endpoint to examine potential changes in
dementia-relevant mechanisms after 16 weeks of treatment
with purified anthocyanin containing capsules, in people with
increased risk of dementia. As a secondary endpoint we also
explored the potential change in a battery of cognitive tests.
MATERIALS AND METHODS
Material
Participants were recruited from the outpatient Memory and
Cardiology clinics at Stavanger University Hospital in Norway
during 2015 and 2016. Eligible for this study were patients
with MCI or mild dementia and/or stable non-obstructive
coronary artery disease (CAD). Potential participants identified
at the respective outpatient clinics were contacted for a
telephone interview by a study doctor, regarding inclusion
and exclusion criteria. Participants were also recruited from
the dementia disease initiation (DDI) study (Fladby et al.,
2017). Inclusion criteria were age ≥50 years and being
on stable medication, including nutraceuticals for the past
3 months, and either (a) confirmed CAD without physiologically
significant stenosis evaluated by coronary angiography, or
(b) having MCI or mild dementia according to ICD 10
(World Health Organization [WHO], 1992).
Exclusion criteria were moderate to severe dementia
[operationalized as a mini-mental status exam (MMSE) (Folstein
et al., 1975) score < 24], clinically significant depression [15–item
Geriatric Depression Scale (GDS-15) (Mitchell et al., 2010)
score ≥ 7], unstable CAD, heart failure in need of treatment,
having taken Medox R© during the past 3 months, using Warfarin,
heparin or non-vitamin K antagonist oral anticoagulants
(NOAC), inflammatory illnesses such as rheumatoid arthritis
and other severe illness with <5 years expected survival. Any
treatment with vitamins, minerals or nutraceuticals had to
have remained stable for the last 3 months prior to inclusion
and during the study. Healthy normal controls (NC) (n = 20)
recruited from the staff at Stavanger University Hospital and
through acquaintances, were ≥50 years, had stable medication,
and had not been taking Medox R© for the last 3 months. This
group provided blood samples at inclusion and 16 weeks later,
but did not take Medox R© or other interventions, and did not
perform the cognitive test battery. The rationale for including
this comparison group was to have a reference group with
respect to any observed changes in the blood analyses in the
intervention group.
Ethics Statement
All participants provided written informed consent, and the
study has been approved by the Regional Ethics Committee
(Approval 2014/1966). The study has been registered at
ClinicalTrials.gov (NCT02409446).
Intervention, Design, and Assessment
Intervention
The participants were given open-label Medox R© capsules,
provided free of charge by the manufacturer Medpalett AS,
Sandnes, Norway. Medox R© capsules, which contain specific
quantities of natural purified anthocyanins from bilberry
(Vaccinium myrtillus) and blackcurrant (Ribes nigrum), have
been used previously in human studies (Karlsen et al., 2007).
The production of the Medox R© capsule (Hassellund et al.,
2013), and its anthocyanin content (Qin et al., 2009) have been
described previously.
The capsules were dispensed at inclusion in the study,
and the participants were instructed to consume two 80 mg
anthocyanin capsules twice daily for a total daily intake of 320 mg
anthocyanins for 16 weeks. This dosage was chosen because it has
previously been shown to have biological effects (Qin et al., 2009;
Zhu et al., 2011; Li et al., 2015) and found to be safe in use (Qin
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et al., 2009). A review found that doses up to 640 mg/day showed
no adverse events (Wallace et al., 2016).
Participants were instructed to maintain their dietary and
lifestyle habits in order to avoid interferences in the study results.
Design and Assessment
At inclusion, all participants underwent a physical examination,
including standardized blood pressure measurement,
electrocardiogram (ECG), and blood tests. In addition a
cognitive test battery (see below) was administered, including
the MMSE and GDS-15. Following standardized procedures,
participants provided blood samples in the morning after
having been fasting for at least 8 h, before and after 16 weeks
of treatment. They were contacted by telephone after 8 weeks
regarding safety and compliance.
Blood Sampling and Analyses
Blood was collected, centrifugated, and stored at −80 ◦C
until analysis according to standardized procedures. The serum
samples were analyzed for lipids (total cholesterol, triglycerides,
HDL- and LDL cholesterol) and fasting glucose using Architect
c16000 TM (Abbott Diagnostics, Chicago, IL, United States)
and HbA1c using Variant II turbo (BioRad, Hercules, CA,
United States) at Stavanger University Hospital.
Markers of inflammation were analyzed after completion
of the study by The Lipid Research Group, Department
of Clinical Sciences, University of Bergen, Bergen, Norway.
Concentrations of cytokines were measured in serum using
the Bio-Plex ProTM Human Cytokine 8-plex assay (Cat.:
M50000007A) which included GM-CSF, IFN-γ, IL-2, IL-4, IL-6,
IL-8, IL-10, and TNF-α, in addition to five Bio-Plex Pro Human
Cytokine single-plexes: MCP-1 (Cat.: 171B5021M), RANTES
(Cat.: 171B5025M), G-CSF (Cat.: 171B5017M), IL-17 (Cat.:
171B5014M), and IL-Iβ (Cat.:171B5001M). All plexes were
manufactured by Bio-Rad (Hercules, CA, United States). The
cytokines were detected by the Bio-PlexTM 200 System and
determined with the Bio-Plex Manager Software 6.1. The samples
were prepared as described in the protocol (Cat.: 10014905) with
a dilution factor of three.
Anthocyanin metabolites were measured in plasma after
completion of the study at Department of Nutritional Sciences,
School of Life Course Sciences, Faculty of Medicine and
Life Sciences, King’s College London, using a method based
on microelution solid phase extraction followed by liquid
chromatography and mass spectrometry, using authentic
standards, as previously described with some modifications
(Feliciano et al., 2016). The detection of plasma (poly)phenol
metabolites was performed on a ExactiveTM Orbitrap Mass
Spectrometer (Thermo Scientific, Waltham, CA, United States)
after separation on an Accela 1250 pump UHPLC system
(Thermo Scientific, Waltham, CA, United States). The
autosampler injected 5 µL of each sample in a Zorbax Eclipse
Plus RRHD column 2.1 mm × 50 mm, 1.8 m with a compatible
Eclipse Plus guardcolumn 2.1 mm × 5 mm, 1.8 m (Agilent,
Waldbronn, Germany). The mobile phase consisted of 0.1%
HCOOH (solvent A) and acetonitrile with 0.1% HCOOH
(solvent B) in a 10 min gradient program. Quantification
analysis of the plasma (poly)phenols was done using Xcalibur 2.2
(Thermo Scientific, Waltham, CA, United States).
Cognitive Tests
Verbal memory function was assessed using the Norwegian
adaptation of the Ten Word List Learning and Recall from
the CERAD battery (Morris et al., 1989), a three part test;
word list learning, word list delayed recall, and word list
delayed recognition.
Executive functioning was assessed by the Trail Making Test
(TMT) A and B (Reitan and Wolfson, 1985) and Stroop Golden
(Golden, 1976). The Trail Making Tests A and B are tests of
psychomotor speed and attention shifting (Ashendorf et al.,
2008), while Stroop Golden is a test used to evaluate cognitive
speed and inhibition (Scarpina and Tagini, 2017).
Safety
Participants were contacted by phone at week 8 to ask about
potential side-effects and adverse events (AE).
The safety blood tests included hemoglobin, thrombocytes,
kidney function and liver function tests, which were measured
at both baseline and study-end.
Compliance
Participants were contacted by phone at week 8 and asked
about adherence to the protocol. Specifically, they were asked
whether they had been taking Medox R© capsules as instructed, and
they were reminded about keeping the empty blister packages.
Protocol adherence was also assessed by collecting and counting
the empty blister packages and left-over capsules at study-end.
Statistical Analyses
Descriptive statistics are presented as medians and interquartile
ranges (IQR), and illustrated using Box plots. Most data were
not normally distributed and thus the main analyses were
non-parametric. The Mann–Whitney U test and the Chi-square
test were used for between-group comparisons. Changes from
baseline to follow-up at 24 weeks within groups were analyzed
with the Wilcoxon Signed Rank test. For all tests p ≤ 0.05 was
considered statistically significant.
Supplementary parametric analyses were performed, from
which we present means, standard deviations (SD), and p-values
from paired and independent samples t-tests.
The IBM SPSS statistical package version 24 was used for all
statistical analyses.
RESULTS
During the period May 2015 to September 2016, 33 participants
started anthocyanin supplementation, of whom 27 (8 MCI and 19
CAD) completed the study (6 were excluded for administrative
and logistical reasons) (Figure 1). The NC were included in the
period December 2016 to February 2017. No subjects with mild
dementia were included.
Baseline characteristics are shown in Table 1.
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FIGURE 1 | Enrolment of participants. N, number.
TABLE 1 | Baseline characteristics.
Active (n = 27) Controls (n = 20)
Median (IQR) Median (IQR)
Women, count (%) 9 (33) 11 (55)
Age (years) 61 (55− 70) 58 (55− 62)
CAD, count (%) 19 (70)
Education (years) 11.5 (10− 14)
BMI 27.7 (26.0− 30.3)
Lipid lowering therapy, count (%) 19 (70)




Dietary supplement, count (%) 18 (67)
CAD, coronary artery disease; BMI, body mass index; IQR, interquartile range.
Only IL-8, MCP-1, CCL-5/RANTES [regulated on activation,
normal T-cell expressed and secreted (RANTES)] and TNF
were available for statistical analyses, as the other inflammation
markers did not reach measurement thresholds. The findings are
summarized in Table 2 and Supplementary Figures S1–S3.
The only significant between-group difference was for
1RANTES (difference from baseline to study end) which
decreased in the supplementation group and increased in the NC
group (Table 2).
When analyzing the groups separately, significant increases
were found in total cholesterol and triglycerides in the
anthocyanin supplementation group (AG) from baseline to
study end (Table 2), and MCP-1 which increased in the NC
group (Table 2).
No significant changes were found for fasting glucose and
HbA1c in the AG group.
A total of 29 plasma anthocyanin metabolites were quantified
(Table 3 and Supplementary Figure S4). When comparing the
two groups, a statistically significant difference was found for
two metabolites (o-Coumaric acid and Dihydroferulic acid-4-O-
Sulfate), which both had a larger decrease in the AG than in the
NC group (Table 3).
In the AG, there was a statistically significant increase in
five of the metabolites (Pyrogallol-2-O-sulfate, Protocatechuic
acid-3-O-sulfate, Pyrogallol-1-O-sulfate, Ferulic acid-4-O-
β-D-glucuronide, Isoferulic_acid-3-O-β-D-glucuronide)
and a statistically significant decrease in five other
metabolites (3-Hydroxyhippuric acid, 4-Hydroxybenzaldehyde,
Dihydroferulic acid-4-O-Sulfate, m-Coumaric acid, o-Coumaric
acid) after 16 weeks of anthocyanin consumption in
comparison with baseline.
In the NC group, there was a statistically significant
decrease in four metabolites (Protocatechuic acid, 3,4-
Dihydroxyphenylacetic acid, 4-Hydroxybenzaldehyde and
o-Coumaric acid), whereas there were no statistically significant
increases in any of the metabolites.
The cognitive test scores improved in the intervention group,
with improvements for CERAD learning (p = 0.016), recall
(p < 0.001) and recognition (p = 0.047) and for STROOP
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TABLE 2 | Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants.
Active (n = 27) Control (n = 20) Active vs. control
Median (IQR) p∗ Median (IQR) p∗ p#
Cholesterol (mmol/L) Cholesterol
Pre 4.0 (3.1 to 5.5) 5.1 (4.5 to 5.5)
Post 4.6 (3.3 to 6.0) 5.1 (4.6 to 5.6)
Diff 0.2 (0.1 to 0.7) 0.009 0.1 (− 0.2 to 0.5) 0.29 0.34
HDL (mmol/L) HDL
Pre 1.2 (1.0 to 1.4) 1.5 (1.1 to 1.7)
Post 1.2 (1.1 to 1.5) 1.4 (1.2 to 1.8)
Diff 0.0 (− 0.1 to 0.1) 0.81 0.1 (− 0.1 to 0.1) 0.21 0.23
LDL (mmol/L) LDLn = 19
Pre 2.4 (1.8 to 3.9) 3.3 (2.9 to 3.9)
Post 3.0 (1.8 to 4.3) 3.3 (2.8 to 4.0)
Diff 0.1 (− 0.1 to 0.3) 0.21 0.0 (− 0.1 to 0.4) 0.62 0.72
Triglycerides (mmol/L) Triglycerides
Pre 1.0 (0.7 to 1.4) 0.9 (0.6 to 1.3)
Post 1.0 (0.7 to 1.7) 0.9 (0.6 to 1.8)
Diff 0.1 (0.7 to 1.7) 0.016 0.0 (− 0.1 to 0.4) 0.072 0.84
Fasting glucose (mmol/L) Fasting glucose
Pre 5.4 (4.9 to 5.6) 5.3 (5.0 to 5.6)
Post 5.5 (5.3 to 6.3) 5.0 (4.8 to 5.7)
Diff 0.2 (− 0.1 to 0.4) 0.058 −0.2 (− 0.4 to − 0.03) 0.009 0.71
HbA1c (%) HbA1c
Pre 5.8 (5.6 to 6.1) 5.6 (5.4 to 5.8)
Post 5.8 (5.6 to 6.1) 5.4 (5.2 to 5.6)
Diff 0.0 (− 0.1 to 0.1) 0.87 −0.05 (− 0.2 to 0.0) 0.057 0.11
IL-8 (mmol/L) IL-8
Pre 9.0 (7.7 to 10.3) 7.5 (7.2 to 8.4)
Post 9.2 (6.9 to 11.1) 7.8 (7.2 to 8.9)
Diff 0.0 (− 1.5 to 1.2) 0.80 0.2 (− 1.0 to 1.5) 0.79 0.41
MCP-1 (pg/mL) MCP-1
Pre 42.2 (10.3 to 59.4) 51.7 (40.9 to 70.2)
Post 41.3 (11.1 to 60.2) 52.8 (45.1 to 93.7)
Diff 0.0 (− 5.4 to 1.7) 0.55 1.9 (0.2 to 17.5) 0.014 0.95
RANTES (pg/mL) RANTES
Pre 9206 (8172 to 9833) 8800 (8370 to 9761)
Post 8918 (8046 to 9942) 9164 (8651 to 10027)
Diff −161 (− 730 to 677) 0.81 19.09 (− 633 to 1105) 0.41 0.003
TNFa (pg/mL) TNFan = 19
Pre 10.1 (7.8 to 13.3) 6.5 (6.1 to 10.9)
Post 9.9 (6.5 to 13.9) 8.0 (5.8 to 11.4)
Diff 0.9 (− 2.8 to 2.9) 0.74 −0.4 (− 1.5 to 3.9) 0.66 0.26
RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted); Diff, median difference between baseline and follow up serum measurements;
IQR, interquartile range; mmol/L, millimol/liter; pg/mL, picomol/liter. ∗The within group difference from baseline to study end. #The between group differences for 1
(difference from baseline to study end).
test word (p < 0.001) and color (p = 0.044) (Table 4 and
Supplementary Figures S5–S7).
Overall, findings using parametric analyses differed only
marginally from the non-parametric findings reported above
(Supplementary Tables S1, S2).
The compliance was good. More than 85% of the
participants returned at least 90% of the empty blister
packages. The anthocyanins were well tolerated, and
none of the participants withdrew due to adverse effects.
Blood tests taken for safety reasons were all within a
clinically acceptable range. Increased bleeding tendency
was not observed.
DISCUSSION
In this pilot study anthocyanin supplementation was well
tolerated, without any AE, and the compliance was good.
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TABLE 3 | Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with supplementation (active) and for control participants.
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Methylpyrogallol-O-sulfate
Pre 33.1 (17.5 to 52.5) 26.2 (10.2 to 67.6)
Post 45.5 (24.1 to 104.2) 20.6 (7 to 65.3)
Diff 15.6 (− 3.3 to 70.7) 0.068 −1.7 (− 23.8 to 13.0) 0.85 0.14
Pyrogallol-2-O-sulfate
Pre 36.4 (17.2 to 110.5) 58.4 (20.4 to 102.4)
Post 63.8 (41.5 to 199.1) 35.2 (21.2 to 93.1)
Diff 17.5 (− 8.3 to 106.4) 0.001 −12.3 (− 82.4 to 32.1) 0.41 0.89
Protocatechuic acid-3-O-sulfate
Pre 3.5 (0.3 to 11.1) 5.4 (1.6 to 10.1)
Post 11.0 (5.5 to 26.5) 6.5 (0.3 to 16.4)
Diff 6.2 (0.0 to 21.6) 0.007 0.8 (− 6.3 to 10.1) 0.81 0.071
1-Methylpyrogallol-O-sulfate
Pre 44.7 (29.2 to 77.3) 60.8 (34.8 to 123)
Post 52.7 (33.6 to 97.2) 71.8 (30.3 to 106)
Diff 12.8 (− 19.6 to 32.7) 0.14 10.4 (− 27.8 to 65.5) 0.60 0.70
4-Methylgallic-3-O-sulfate
Pre 14.0 (5.6 to 23.8) 13.1 (8.5 to 28.7)
Post 12.8 (7.1 to 24.6) 12.3 (7.3 to 21.1)
Diff 1.6 (− 7.8 to 14.3) 0.65 −5.5 (− 15.6 to 12.0) 0.35 0.25
4-Hydroxybenzoic acid-O-sulfate
Pre 2027 (1211 to 4284) 2664 (1455 to 3764)
Post 1704 (772 to 3597) 1723 (420 to 4354)
Diff −97 (− 1039 to 234) 0.14 −924 (− 2691 to 1046) 0.26 0.67
4-Hydroxyhippuric acid
Pre 164 (93 to 272) 145 (117 to 275)
Post 123 (94 to 283) 111 (91 to 163)
Diff 6 (− 84 to 44) 0.84 −33 (− 236 to 33) 0.079 0.21
Protocatechuic acid
Pre 57.5 (22.0 to 106.8) 66.6 (35.5 to 127)
Post 51.3 (29.4 to 114.2) 48.7 (5.0 to 76.9)
Diff 1.6 (− 49.7 to 51.3) 0.75 −22.0 (− 85.2 to 17.2) 0.049 0.057
Pyrogallol-1-O-sulfate
Pre 25.6 (15.3 to 61.2) 55.1 (25.3 to 106.5)
Post 52.9 (25.5 to 97.6) 63.8 (41.4 to 94.4)
Diff 18.8 (1.5 to 68.4) 0.006 −2.9 (− 36.3 to 45.7) 0.85 0.093
3,4-Dihydroxyphenylacetic acid
Pre 174 (100 to 237) 122 (85 to 197)
Post 106 (84 to 213) 98 (75 to 163)
Diff −26 (− 135 to 69) 0.20 −33 (− 67 to 2) 0.044 0.97
Catechol-O-sulfate
Pre 5518 (2718 to 8056) 5986 (4284 to 7527)
Post 4640 (3183 to 7843) 4690 (3576 to 5627)
Diff 367 (− 2569 to 1608) 0.61 −937 (− 3502 to 2010) 0.25 0.67
Vanillic acid-4-O-sulfate
Pre 30.6 (9.5 to 47.8) 24.6 (9.6 to 39.6)
Post 26.2 (9.8 to 42.3) 22.6 (7.9 to 34.7)
Diff −6.5 (− 27.6 to 10.8) 0.20 −5.2 (− 15.0 to 23.8) 1.0 0.41
3-Hydroxyhippuric acid
Pre 709 (191 to 3060) 451 (269 to 1343)
(Continued)
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TABLE 3 | Continued
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Post 339 (63 to 1233) 162 (35 to 599)
Diff −503 (− 1246 to − 55) 0.002 −183 (− 1117 to 196) 0.10 0.28
p-Coumaric acid-4-O-β-D-glucuronide
Pre 0.29 (0.00 to 0.52) 0.23 (0.00 to 0.46)
Post 0.21 (0.11 to 0.41) 0.17 (0.00 to 0.30)
Diff −0.07 (− 0.26 to 0.24) 0.92 0.01 (− 0.20 to 0.20) 0.94 0.84
Isovanillic acid-3-O-sulfate
Pre 2.3 (0.0 to 8.3) 5.5 (0.0 to 19.1)
Post 2.8 (0.0 to 11.3) 5.7 (0.3 to 14.4)
Diff 0.0 (− 3.5 to 11.3) 0.90 −1.1 (− 10.6 to 3.6) 0.50 0.48
Catechol-O-1-glucuronide
Pre 1.7 (0.0 to 9.2) 2.2 (0.1 to 8.0?)
Post 4.6 (1.6 to 14.2) 1.1 (0.1 to 6.6)
Diff 1.5 (− 1.5 to 8.8) 0.075 0.1 (− 2.2 to 1.7) 0.97 0.14
Ferulic acid-4-O-β-D-glucuronide
Pre 4.3 (0.4 to 33.4) 7.7 (1.0 to 19.4)
Post 19.4 (2.6 to 59.3) 5.8 (1.1 to 21.5)
Diff 5.5 (0.2 to 31.4) 0.013 −0.3 (− 5.9 to 15.4) 0.98 0.064
Hippuric acid
Pre 17680 (9444 to 55008) 24075 (11958 to 39646)
Post 15225 (8654 to 40673) 12211 (11086 to 28936)
Diff −3572 (− 18398 to 1041) 0.068 −2788 (− 15907 to 4975) 0.33 0.68
4-Methylcatechol-O-sulfate
Pre 1630 (815 to 3580) 1209 (753 to 1889)
Post 1228 (691 to 2722) 997 (647 to 1899)
Diff −182 (− 1087 to 733) 0.47 −221 (− 617 to 255) 0.28 0.95
4-Hydroxybenzaldehyde
Pre 72.6 (40.3 to 130) 81.2 (58.4 to 105)
Post 53.5 (48.9 to 93.3) 48.7 (39.5 to 75.5)
Diff −24.8 (− 56.1 to 6.5) 0.029 −34.3 (− 52.8 to − 6.8) 0.019 0.78
Ferulic acid-4-O-sulfate
Pre 2.3 (0.5 to 7.0) 4.0 (0.0 to 12.3)
Post 1.9 (0.8 to 23.8) 6.1 (1.6 to 9.7)
Diff 0.5 (− 2.9 to 21.1) 0.20 1.1 (− 7.7 to 9.1) 0.55 0.69
Dihydroisoferulic acid-3-O-sulfate
Pre 7.2 (0.0 to 17.5) 4.9 (0.0 to 14.1)
Post 9.2 (2.1 to 23.7) 7.6 (1.0 to 19.4)
Diff 1.0 (− 7.5 to 8.6) 0.47 0.9 (− 6.9 to 13.0) 0.69 0.94
Isoferulic acid-3-O-sulfate
Pre 1.1 (0.3 to 2.3) 0.8 (0.4 to 5.7)
Post 4.5 (0.4 to 13.7) 1.5 (0.3 to 8.6)
Diff 0.6 (− 1.7 to 10.2) 0.25 0.4 (− 1.6 to 2.4) 0.55 0.67
Dihydroisoferulic acid-3-O-β-D-glucuronide
Pre 19.1 (7.2 to 45.7) 25.8 (2.5 to 82.4)
Post 20.7 (8.1 to 60.8) 16.1 (5.4 to 43.4)
Diff 1.2 (− 15.4 to 34.5) 0.47 −4.9 (− 70.9 to 27.7) 0.55 0.31
Isoferulic acid-3-O-β-D-glucuronide
Pre 22.3 (5.2 to 67.5) 21.2 (1.8 to 54.6)
Post 27.3 (8.5 to 136.4) 21.3 (5.7 to 58.6)
Diff 24.4 (− 18.0 to 96.2) 0.044 2.7 (− 10.1 to 36.8) 0.55 0.21
(Continued)
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TABLE 3 | Continued
Active (n = 27) Control (n = 20) Active vs.
control
nmol/L Median (IQR) p∗ Median (IQR) p∗ p#
Dihydroferulic acid-4-O-sulfate
Pre 3.7 (1.2 to 8.3) 1.9 (0.2 to 3.6)
Post 1.6 (0.9 to 5.1) 2.7 (1.4 to 5.2)
Diff −1.5 (− 3.1 to − 0.3) 0.006 0.8 (− 0.9 to 2.9) 0.31 0.010
3-(3-hydroxyphenyl)propanoic acid
Pre 805 (44 to 2377) 350 (14 to 1479)
Post 470 (72 to 4306) 414 (112 to 1624)
Diff 29 (− 495 to 831) 0.43 36 (− 917 to 345) 0.74 0.76
m-Coumaric acid
Pre 111 (35 to 146) 84 (63 to 110)
Post 55 (38 to 78) 58 (53 to 85)
Diff −62 (− 82 to 16) 0.014 −28 (− 58 to 2) 0.093 0.33
o-Coumaric acid
Pre 218 (81 to 356) 125 (81 to 234)
Post 87 (47 to 158) 81 (50 to 162)
Diff −116 (− 230 to − 35) <0.001 −36 (− 111 to − 1) 0.006 0.019
Diff, median difference between baseline and follow up plasma measurements; IQR, interquartile range; nmol/L = nanomol/liter. ∗The within group difference from baseline
to study end. #The between group differences for 1 (difference from baseline to study end).
This indicates that larger RCTs might be feasible, to confirm
exploratory results in the current pilot study.
Our findings are somewhat inconclusive. While some
cognitive improvements were observed in the AG, there were
no significant changes in serum levels of some risk factors
for dementia; i.e., fasting glucose, HbA1c or pro-inflammatory
cytokines. There was a non-significant decrease in serum levels
of RANTES in the AG and a non-significant increase in the NC
during the study period. However, the between-group difference
in 1 serum levels of RANTES was statistically significant.
Furthermore, we observed a significant increase in serum
levels of total cholesterol and triglycerides in AG. The lipid profile
of the NC group did not change significantly, and since we have
no information about statin use or use of other lipid lowering
medications in the NC group, the observed difference should be
interpreted cautiously.
Previous studies using Medox R© have shown a statistically
significant increase in HDL-cholesterol (Qin et al., 2009; Zhu
et al., 2011; Hassellund et al., 2013) and a decrease in
LDL-cholesterol (Qin et al., 2009; Zhu et al., 2011). This is of
clinical interest, as higher HDL-cholesterol is associated with
lower cardiovascular risk (Barter et al., 2007), while high levels of
total cholesterol, triglycerides and LDL are associated with higher
cardiovascular risk (Stone et al., 2014).
The differences in the findings between our study and these
previous studies might be due to differences in participants, as
well as in anthocyanin supplementation dose and duration, or
other factors. Furthermore, other studies included dyslipidemic
and hypercholesterolemic participants not using statins or any
other lipid lowering treatment (Qin et al., 2009; Zhu et al., 2011),
whereas in our study, the median cholesterol at baseline in the
intervention group was 4.0 mmol/l, in addition 70% were taking
statins or other lipid lowering medication.
Regarding the inflammation markers, RANTES promotes
activation and migration of leukocytes and mediates
neuroinflammation and brain microvascular dysfunction
(Appay and Rowland-Jones, 2001; Dénes et al., 2010; Yilmaz and
Granger, 2010). There was a significant between-group difference
for 1RANTES, although anthocyanin supplementation did not
significantly reduce RANTES in the AG. Still, our results are
consistent with similar findings in a randomized, double-blind
trial in hypercholesterolemic individuals consuming purified
anthocyanins for 24 weeks (Song et al., 2014), and in a
parallel-designed, placebo-controlled trial (Karlsen et al., 2007).
Other studies did not report a reduction of pro-inflammatory
mediators after anthocyanin supplementation (Hassellund et al.,
2013; Kent et al., 2015). Therefore, the anti-inflammatory effect
of anthocyanins and the potential to reduce neuroinflammation
and brain microvascular dysfunction associated with cognitive
decline in adults at risk of dementia (Grammas, 2011) should be
studied in larger randomized studies.
The beneficial effect of anthocyanins might possibly be
due to their degradation products and metabolites (Feliciano
et al., 2016) as absorption of intact anthocyanins is reported
to be low (Zhong et al., 2017). Rodriguez-Mateos et al.
quantified metabolites in plasma after blueberry consumption,
and showed that anthocyanin-derived metabolites correlated
with in vivo effects (Rodriguez-Mateos et al., 2013, 2019).
Furthermore, circulating anthocyanin metabolites were shown
to improve vascular function when injected in an in vivo
model of vascular function, and cardiovascular benefits after
consumption of anthocyanins were linked with anthocyanin
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TABLE 4 | Changes from baseline to 16 weeks follow-up in cognitive variables, for
participants with supplementation (active).
Active (n = 27)
Median (IQR) p∗
CERAD (points) Learning
Pre 20 (16 to 22)
Post 21 (17 to 25)
Diff 2 (− 1 to 3) 0.016
Recall
Pre 6 (4 to 8)
Post 7 (5 to 9)
Diff 1 (0 to 2) <0.001
Recognition
Pre 20 (16 to 20)
Post 20 (19 to 20)
Diff 0 (0 to 1) 0.047
TMT A (sec)
Pre 32 (21 to 53)
Post 34 (23 to 39)
Diff −2 (− 6 to 2) 0.081
TMT Bn = 19 (sec)
Pre 85.50 (62.25 to 118)
Post 69.50 (56 to 100.75)
Diff −2.0 (− 19.75 to 2.25) 0.16
STROOP (score) Word
Pre 87 (72 to 67)
Post 87 (80 to 103)
Diff 6 (1 to 10) <0.001
Color
Pre 61 (52 to 67)
Post 62 (54 to 69)
Diff 2 (− 1 to 6) 0.044
Word-color
Pre 34 (29 to 41)
Post 34 (28 to 41)
Diff 0 (− 3 to 5) 0.67
TMT, Trail Making Test; Diff, median difference between baseline and follow up
results in cognitive tests; IQR, interquartile range. ∗The within group difference from
baseline to study end.
metabolites as mediators of change in cellular gene programs
(Rodriguez-Mateos et al., 2019).
In our study, we were able to measure a total of 29 anthocyanin
metabolites. The results were conflicting, as we found various
anthocyanin metabolites to be both significantly increasing and
decreasing in the AG. In the NC group as well, we found
significant changes. This is in line with findings in another
study reporting an increase of some metabolites, and a decrease
in others after ingestion of anthocyanins over time (Feliciano
et al., 2016). A possible explanation for our results could be high
inter-individual variability and the influence of the background
diet on the concentration of these compounds in blood, as some
of these metabolites could arise from the consumption of other
anthocyanin-rich foods such as berries and red wine or other
food components in the diet. It is also possible that the results
could be related to the handling and analysis of the blood samples.
As far as we know, the presence of anthocyanin metabolites in
plasma after Medox R© use is reported in only one other clinical
study, where 8 out of 17 anthocyanin metabolites were found to
be significantly increased. However, this was analyzed in blood
samples collected 1–3 h after ingestion of the morning dose of
anthocyanins (320 mg), and not after daily consumption and an
overnight fast (Hassellund et al., 2013).
The improvement on several cognitive tests should be
interpreted cautiously due to potential learning effects related
to the relatively short test–retest interval, and the lack of
a comparison group. Nonetheless, our results are in line
with previous smaller studies involving participants with MCI,
reporting improved cognition after ingestion of anthocyanins
(Krikorian et al., 2010a,b). Our results are also in line with
the results of a randomized, double-blinded, placebo-controlled
study reporting improved episodic memory after 3 months of
anthocyanin supplementation (Whyte et al., 2018).
Intake of anthocyanin capsules in the dosage of 320 mg/day
appears to be well tolerated and safe. None of the safety
blood tests were found to be out of a clinically acceptable
range or necessitating medical follow-up after study-end. This
is consistent with previous studies (Karlsen et al., 2007;
Qin et al., 2009).
The major limitations of this pilot study are the
non-randomized open-label design, the small sample size,
and the relatively short intervention period. Although all the
participants were told not to change their lifestyle during the
intervention period, we have no data on this. Further we had
no detailed dietary assessment, and thus we cannot exclude the
possibility of differences in the background diet between the
groups before or during the study. However, the participants
were instructed to maintain their dietary and lifestyle habits
during the study period, and to take the capsules 30 min before or
120 min after meals, as concomitant ingestion of certain types of
food may counteract the effect of flavonoids (Lorenz et al., 2007).
The NC were recruited separately and differed from the
participants by being a healthy group that did not receive
any intervention, and did not perform cognitive testing. Thus
power calculations for further studies might be compromised.
However, we provide descriptive statistics including variance
measurements which may be helpful in planning sample size
in later studies.
An important strength of our study is the well characterized
combination of nutraceuticals used, which facilitates comparison
with other studies regarding both source of anthocyanins and
dosage. Of note, this is, to our knowledge, the first study on
cognitive function in adults with increased risk of dementia
where Medox R© is being used as the source of anthocyanin.
Thus our study might also facilitate investigation of the effect
of different proprietary blueberry formulatons, shown by Whyte
et al. to be of importance (Whyte et al., 2018).
All things considered, adequately powered, randomized
studies are warranted to better understand how anthocyanins
and their metabolites may affect relevant mechanisms, including
their possible protective role in epigenetic modifications
that potentially benefit the aging brain and reduce the
risk for dementia.
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FIGURE S1 | Changes from baseline to 16 weeks follow-up in serum lipids, for
participants with anthocyanin supplementation. mmol/L, millimole/liter.
FIGURE S2 | Changes from baseline to 16 weeks follow-up in serum fasting
glucose and HbA1c, for participants with anthocyanin supplementation. HbA1a,
glycosylated hemoglobin; mmol/L, millimole/liter.
FIGURE S3 | Changes from baseline to 16 weeks follow-up in serum cytokines,
for participants with anthocyanin supplementation. RANTES;CCL-5/RANTES
(regulated on activation, normal T-cell expressed and secreted). pg/mL,
picomolar/milliliter.
FIGURE S4 | Changes from baseline to 16 weeks follow-up in plasma
anthocyanin metabolites, for participants with and without anthocyanin
supplementation. Measurement unit: nmol/L, nanomolar/liter, except for hippuric
acid (nmol/10L) and coumaric acid-4-O-β-D-glucuronide (nmol/0.033L).
FIGURE S5 | Changes from baseline to 16 weeks follow-up in CERAD.
FIGURE S6 | Changes from baseline to 16 weeks follow-up in Trail Making Test
(TMT). Sec, seconds.
FIGURE S7 | Changes from baseline to 16 weeks follow-up in Stroop test.
TABLE S1 | Changes from baseline to 16 weeks follow-up in serum variables, for
participants with supplementation (active) and for control participants. x̄, mean;
SD, standard deviation; ∗The within group difference from baseline to study end
tested with paired-samples t-test. $ independent samples t-test for the between
group differences for 1 (difference from baseline to study end). #With Welch
correction for heteroscedasticity. RANTES;CCL-5/RANTES (regulated on
activation, normal T-cell expressed and secreted). Diff, mean difference between
baseline and follow up results in serum measurements.
TABLE S2 | Changes from baseline to 16 weeks follow-up in cognitive variables,
for participants with supplementation (active). x̄, mean; SD, standard deviation;
TMT, Trail Making Test; Diff, mean difference between baseline and follow up
results in cognitive tests. ∗The within group difference from baseline to study end
tested with paired-samples t-test.
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